Will Guardant Health (GH) be Able to Sustain its Growth?

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund posted a return of -5.18% gross of fees compared to -3.60% return for the Russell 1000 Growth Index. Stock selection and security allocation led the strategy to underperform during the quarter relative to its benchmark. In addition, you can check the top 5 holdings of the fund to know its best picks in 2022.

Aristotle Atlantic highlighted stocks like Guardant Health, Inc. (NASDAQ:GH) in the Q3 2022 investor letter. Headquartered in Redwood City, California, Guardant Health, Inc. (NASDAQ:GH) is a biotechnology company. On November 23, 2022, Guardant Health, Inc. (NASDAQ:GH) stock closed at $50.07 per share. One-month return of Guardant Health, Inc. (NASDAQ:GH) was 4.66%, and its shares lost 53.31% of their value over the last 52 weeks. Guardant Health, Inc. (NASDAQ:GH) has a market capitalization of $5.129 billion.

Aristotle Atlantic made the following comment about Guardant Health, Inc. (NASDAQ:GH) in its Q3 2022 investor letter:

Guardant Health, Inc. (NASDAQ:GH) shares were up in the third quarter, bouncing back from weakness in the second quarter. Guardant reported solid 40% year-over-year growth in clinical test volumes and 65% growth in biopharmaceutical test volumes. Shares have been strong in anticipation of the fourth quarter read out from the ongoing Eclipse clinical trial, evaluating Guardant’s test for early detection of colorectal cancer.”

Guardant Health, Inc. (NASDAQ:GH) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 33 hedge fund portfolios held Guardant Health, Inc. (NASDAQ:GH) at the end of the third quarter, which was 35 in the previous quarter.

We discussed Guardant Health, Inc. (NASDAQ:GH) in another article and shared the newest additions to Cathie Wood’s stock portfolio. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.